Cost and evidence gaps remain barriers to approving funding in the NHS for donanemab and lecanemab. Today we’ve published further draft guidance for public consultation that continues to not recommend ...

Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over TA1044 26 February 2025 26 February 2025 Durvalumab with etoposide and either carboplatin or cisplatin for ...

NICE publishes final draft guidance recommending efanesoctocog alfa as an option for treating and preventing bleeding in ...

If you're developing a healthtech product, understanding NICE's priorities is crucial. For 2024/25, NICE is focussing on innovations addressing: ...

Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110] Draft guidance Technology appraisal guidance 27 March ...

Mental wellbeing is about life satisfaction, optimism, self-esteem, feeling in control, having a purpose and a sense of belonging and support. Older people, including those living in care homes, often ...

NICE publishes final draft guidance recommending efanesoctocog alfa as an option for treating and preventing bleeding in people aged 2 and over with severe haemophilia A.

Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer TA1041 19 February 2025 19 February 2025 Selpercatinib for previously treated RET ...

All NICE products on people with learning disabilities. Includes any guidance and quality standards.

The meeting will take place via Zoom, a secure web conferencing tool. The meeting will run from 9:00am to 4:30pm, although this may be subject to change. Joining links and times for each ...

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.